Inhibitors of protein kinases
The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.
1. A method for treating multiple myeloma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
D 1 is cyclopropyl;
R 1 is selected from the group consisting of H, C 1-8 alkyl, amino, aminocarbonyl, hydroxyl, C 1-8 alkoxy, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, oxo, cyano, C 1-8 alkoxycarbonyl, C 3-8 cycloalkyl, aryl, and heterocyclyl; wherein the heterocyclyl is optionally substituted with from 1 to 4 substituents selected from the group consisting of C 1-8 alkyl, halo, oxo, amino, C 1-8 alkoxy, C 1-8 alkylcarbonyl, arylC 1-8 alkoxycarbonyl, aminocarbonyl, arylC 1-8 alkylenecarbonyl, and C 1-8 alkylsulfonyl;
Y 1 is phenyl, optionally substituted with from 1 to 3 R 4a substituents independently selected from the group consisting of C 1-8 alkyl, C 1-8 alkoxyC 1-8 alkyl, aminocarbonyl, hydroxyl, halogen, hydroxy, C 1-8 alkoxy, and C 1-8 alkylsulfonyl;
R 2 is piperazinyl;
and wherein R 2 is further substituted with from 1 to 2 R 4c substituents, each independently selected from the group consisting of C 1-8 alkylcarbonyl and C 1-8 alkylsulfonyl.
2. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound of Formula I has the formula
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound of Formula I has the formula
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the compound of Formula I has the formula
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the compound of Formula I has the formula
or a pharmaceutically acceptable salt thereof.